HKYM Biopharma

Company Drug

HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors

Fineline Cube Jul 11, 2025

Shenzhen-based oncolytic virus specialist HKYM Biopharma has announced receiving the green-light from the National Medical...

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent